Welch KM - Search Results

1

Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.

Reynolds EE, Keiser JA, Haleen SJ, Walker DM, Olszewski B, Schroeder RL, Taylor DG, Hwang O, Welch KM, Flynn MA, et al. Reynolds EE, et al. Among authors: welch km. J Pharmacol Exp Ther. 1995 Jun;273(3):1410-7. J Pharmacol Exp Ther. 1995. PMID: 7791115

2

The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb.

Coe Y, Haleen SJ, Welch KM, Liu YA, Coceani F. Coe Y, et al. Among authors: welch km. J Pharmacol Exp Ther. 2002 Aug;302(2):672-80. doi: 10.1124/jpet.302.2.672. J Pharmacol Exp Ther. 2002. PMID: 12130731

3

Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension.

Haleen S, Schroeder R, Walker D, Quenby-Brown E, Welch K, Hallak H, Uprichard A, Keiser J. Haleen S, et al. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S331-5. doi: 10.1097/00005344-199800001-00092. J Cardiovasc Pharmacol. 1998. PMID: 9595473

4

Pharmacological differences between rat and human endothelin B receptors.

Reynolds EE, Hwang O, Flynn MA, Welch KM, Cody WL, Steinbaugh B, He JX, Chung FZ, Doherty AM. Reynolds EE, et al. Among authors: welch km. Biochem Biophys Res Commun. 1995 Apr 17;209(2):506-12. doi: 10.1006/bbrc.1995.1530. Biochem Biophys Res Commun. 1995. PMID: 7733918

5

Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.

Patt WC, Edmunds JJ, Repine JT, Berryman KA, Reisdorph BR, Lee C, Plummer MS, Shahripour A, Haleen SJ, Keiser JA, Flynn MA, Welch KM, Reynolds EE, Rubin R, Tobias B, Hallak H, Doherty AM. Patt WC, et al. Among authors: welch km. J Med Chem. 1997 Mar 28;40(7):1063-74. doi: 10.1021/jm9606507. J Med Chem. 1997. PMID: 9089328

6

Endothelin B receptors on human endothelial and smooth-muscle cells show equivalent binding pharmacology.

Flynn MA, Haleen SJ, Welch KM, Cheng XM, Reynolds EE. Flynn MA, et al. Among authors: welch km. J Cardiovasc Pharmacol. 1998 Jul;32(1):106-16. doi: 10.1097/00005344-199807000-00017. J Cardiovasc Pharmacol. 1998. PMID: 9676729

7

Butenolide endothelin antagonists with improved aqueous solubility.

Patt WC, Cheng XM, Repine JT, Lee C, Reisdorph BR, Massa MA, Doherty AM, Welch KM, Bryant JW, Flynn MA, Walker DM, Schroeder RL, Haleen SJ, Keiser JA. Patt WC, et al. Among authors: welch km. J Med Chem. 1999 Jun 17;42(12):2162-8. doi: 10.1021/jm980504w. J Med Chem. 1999. PMID: 10377221

8

In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.

Doherty AM, Cody WL, He JX, DePue PL, Cheng XM, Welch KM, Flynn MA, Reynolds EE, LaDouceur DM, Davis LS, et al. Doherty AM, et al. Among authors: welch km. J Cardiovasc Pharmacol. 1993;22 Suppl 8:S98-102. doi: 10.1097/00005344-199322008-00027. J Cardiovasc Pharmacol. 1993. PMID: 7510009

9

Truncated analogues of endothelin and sarafotoxin are selective for the ETB receptor subtype.

Heyl DL, Cody WL, He JX, Flynn MA, Welch KM, Reynolds EE, Doherty AM. Heyl DL, et al. Among authors: welch km. Pept Res. 1993 Sep-Oct;6(5):238-41. Pept Res. 1993. PMID: 8257799

10

Assessment of endothelin receptor subtype-mediated increases of [Ca2+]i in distinct rat cell types using fluorimetric imaging.

Dooley DJ, Geer JJ, Haleen SJ, Probert AW, Welch KM. Dooley DJ, et al. Among authors: welch km. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S192-5. doi: 10.1097/00005344-199800001-00054. J Cardiovasc Pharmacol. 1998. PMID: 9595435

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters